![]() |
Abunda delivers solutions for the life sciences, health & nutrition and functional foods markets. Through our deep knowledge of consumer trends and product innovation, we deliver new technologies, innovations and bioactive ingredients into brands that last. We identify and capture growth opportunities for our clients.
Abunda was founded in 1997 by Peter Leighton, who brings nearly 30 years experience in consumer products, nutrition and biotechnology. Leighton has been responsible for some of the most successful brands on the market, and has been an early leader in the areas of functional foods and science-based nutraceuticals. He has held senior executive positions such as CEO at Advana Science, VP Marketing & Product Development at Natrol (NTOL), Vice President at Galileo Laboratories, SVP Marketing at Weider Nutrition (WNI) and Director of Marketing at InterHealth Nutraceuticals. He is also a frequent industry speaker and contributing writer for many publications.
The real growth and profitability in the sports nutrition category comes from the Active Nutrition segment.
Peter Leighton discusses functional foods at Ingredia 2014's "Rockstar".
We have many additional articles and presentations for you to download. Please click the following link to access them.
billion in 2013 The global market for functional foods & beverages will reach $176.7 billion in 2013 with a CAGR of over 7%. This represents about 5% of the overall US food market.
The US functional food market has grown 31% since 2006. 87% of American consumers are interested in learning about functional foods.
Global volume consumption of probiotics is more than 3X that of omega-3. 81% of Americans ranked probiotics as the most important nutrient.
of Americans wish they could find more convenient sources of nutrition when they're on-the-go. Healthier snack sales are growing at three times the rate of indulgent snacks.
Cranberry juice
sales increased 20% after the results of a 1994 Harvard study demonstrating health benefits.
The U.S. supplement market has progressed steadily from 5.5% annual growth in 2007 to 6.5% in 2008 to 7.5% in 2009, and at least 69% of U.S. adults take them daily.